News & Updates

The oral selective Janus kinase 1/2 inhibitor baricitinib, when added to standard of care (SoC), reduced the risk of mortality among adults hospitalized with COVID-19. However, the primary outcome of disease progression was not met in the baricitinib group, results of the phase III COV-BARRIER study showed.

Treatment with calcifediol shortly after hospitalization with COVID-19 results in a significant reduction in intensive care unit (ICU) admission and death by more than 50 percent, reveals a study. In addition, baseline 25(OH)D levels is negatively associated with both ICU admission and mortality.

Smartwatches, with the support of machine learning algorithms, can perceive face-touching (FT) behaviours and may help contain outbreaks of respiratory infections such as the coronavirus disease 2019 (COVID-19), according to a new study.

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Patients coinfected with the coronavirus disease 2019 (COVID-19) and Chagas disease are more likely to have cardiovascular comorbidities, but do not seem to suffer from worse in-hospital outcomes, a recent study has found.

Data presented at ID Week 2021 show that Clostridioides difficile (CDI), which is known to be hospital-associated, is highly prevalent even in nonhealthcare settings.

Intramuscular administration of single-dose AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab and cilgavimab), significantly reduced the risk of developing symptomatic COVID-19 in adults, according to the PROVENT* study presented at IDWeek 2021.

Access to pre-exposure prophylaxis (PrEP) may be expanded through pharmacies to reach racial minorities of men who have sex with men (MSM) with the highest need but are not being reached, suggest the results of a US study.